5 CONCLUSIONS
Our study confirms that HDM SLIT-tablet (ACARIZAX®) is a safe and
well-tolerated treatment for HDM AR in daily clinical practice.
Adverse events are common but are mostly mild and decrease during the
first year. Clinical scores (CARAT) improve, and symptomatic medication
use decreases with treatment duration. If patients continue therapy,
compliance rates are high and treatment satisfaction is good. However,
with a stopping rate of 14.5% and 18.3% due to adverse events and
motivational reasons, compliance remains the main concern when starting
HDM SLIT-tablet.